Cargando…

Survival and Clinical Outcomes with Telotristat Ethyl in Patients with Carcinoid Syndrome

PURPOSE: The TELEACE study showed reductions in tumor size in patients with neuroendocrine tumors, receiving telotristat ethyl in US clinical practice. Here, we report progression-free survival, time to tumor progression, changes in carcinoid syndrome symptoms, and indictors of overall health. PATIE...

Descripción completa

Detalles Bibliográficos
Autores principales: Metz, David C, Liu, Eric, Joish, Vijay N, Huynh, Lynn, Totev, Todor I, Duh, Mei Sheng, Seth, Kiernan, Giacalone, Susan, Lapuerta, Pablo, Morse, Michael A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7548219/
https://www.ncbi.nlm.nih.gov/pubmed/33116830
http://dx.doi.org/10.2147/CMAR.S276519
_version_ 1783592578372861952
author Metz, David C
Liu, Eric
Joish, Vijay N
Huynh, Lynn
Totev, Todor I
Duh, Mei Sheng
Seth, Kiernan
Giacalone, Susan
Lapuerta, Pablo
Morse, Michael A
author_facet Metz, David C
Liu, Eric
Joish, Vijay N
Huynh, Lynn
Totev, Todor I
Duh, Mei Sheng
Seth, Kiernan
Giacalone, Susan
Lapuerta, Pablo
Morse, Michael A
author_sort Metz, David C
collection PubMed
description PURPOSE: The TELEACE study showed reductions in tumor size in patients with neuroendocrine tumors, receiving telotristat ethyl in US clinical practice. Here, we report progression-free survival, time to tumor progression, changes in carcinoid syndrome symptoms, and indictors of overall health. PATIENTS AND METHODS: This was a retrospective, single arm, pre-post medical chart review of patients with locally advanced or metastatic neuroendocrine tumors and documented carcinoid syndrome receiving telotristat ethyl for at least 6 months. Patients with poorly differentiated tumors, mixed tumor types or conflicting clinical trial enrollment were excluded. Descriptive statistics, Kaplan–Meier and chi-square tests were used to evaluate PFS, tumor progression, changes in symptoms, body weight and ECOG performance status before and after telotristat ethyl initiation. Subgroup analyses were conducted in patients with the same pre- and post-telotristat ethyl background treatment. RESULTS: Anonymized data for 200 patients were provided by 114 physicians; patients received telotristat ethyl for a median of 9 months. Median time to tumor progression was 39.8 months (IQR, 18.7–39.8); most had no tumor progression at 6 (92%) and 12 months (87%). Median progression-free survival was 23.7 months (17.8–39.8); most had progression-free survival at 6 (90%) and 12 months (80%). Results were consistent in the subgroup of 65 patients with the same pre/post background treatment. Nearly all patients had improved carcinoid syndrome symptoms, stable or improved weight and ECOG performance status. CONCLUSION: Patients showed improvements in clinical outcomes and indicators of overall health following treatment with telotristat ethyl in this exploratory pilot study, consistent with previously observed reductions in tumor size.
format Online
Article
Text
id pubmed-7548219
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-75482192020-10-27 Survival and Clinical Outcomes with Telotristat Ethyl in Patients with Carcinoid Syndrome Metz, David C Liu, Eric Joish, Vijay N Huynh, Lynn Totev, Todor I Duh, Mei Sheng Seth, Kiernan Giacalone, Susan Lapuerta, Pablo Morse, Michael A Cancer Manag Res Original Research PURPOSE: The TELEACE study showed reductions in tumor size in patients with neuroendocrine tumors, receiving telotristat ethyl in US clinical practice. Here, we report progression-free survival, time to tumor progression, changes in carcinoid syndrome symptoms, and indictors of overall health. PATIENTS AND METHODS: This was a retrospective, single arm, pre-post medical chart review of patients with locally advanced or metastatic neuroendocrine tumors and documented carcinoid syndrome receiving telotristat ethyl for at least 6 months. Patients with poorly differentiated tumors, mixed tumor types or conflicting clinical trial enrollment were excluded. Descriptive statistics, Kaplan–Meier and chi-square tests were used to evaluate PFS, tumor progression, changes in symptoms, body weight and ECOG performance status before and after telotristat ethyl initiation. Subgroup analyses were conducted in patients with the same pre- and post-telotristat ethyl background treatment. RESULTS: Anonymized data for 200 patients were provided by 114 physicians; patients received telotristat ethyl for a median of 9 months. Median time to tumor progression was 39.8 months (IQR, 18.7–39.8); most had no tumor progression at 6 (92%) and 12 months (87%). Median progression-free survival was 23.7 months (17.8–39.8); most had progression-free survival at 6 (90%) and 12 months (80%). Results were consistent in the subgroup of 65 patients with the same pre/post background treatment. Nearly all patients had improved carcinoid syndrome symptoms, stable or improved weight and ECOG performance status. CONCLUSION: Patients showed improvements in clinical outcomes and indicators of overall health following treatment with telotristat ethyl in this exploratory pilot study, consistent with previously observed reductions in tumor size. Dove 2020-10-07 /pmc/articles/PMC7548219/ /pubmed/33116830 http://dx.doi.org/10.2147/CMAR.S276519 Text en © 2020 Metz et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Metz, David C
Liu, Eric
Joish, Vijay N
Huynh, Lynn
Totev, Todor I
Duh, Mei Sheng
Seth, Kiernan
Giacalone, Susan
Lapuerta, Pablo
Morse, Michael A
Survival and Clinical Outcomes with Telotristat Ethyl in Patients with Carcinoid Syndrome
title Survival and Clinical Outcomes with Telotristat Ethyl in Patients with Carcinoid Syndrome
title_full Survival and Clinical Outcomes with Telotristat Ethyl in Patients with Carcinoid Syndrome
title_fullStr Survival and Clinical Outcomes with Telotristat Ethyl in Patients with Carcinoid Syndrome
title_full_unstemmed Survival and Clinical Outcomes with Telotristat Ethyl in Patients with Carcinoid Syndrome
title_short Survival and Clinical Outcomes with Telotristat Ethyl in Patients with Carcinoid Syndrome
title_sort survival and clinical outcomes with telotristat ethyl in patients with carcinoid syndrome
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7548219/
https://www.ncbi.nlm.nih.gov/pubmed/33116830
http://dx.doi.org/10.2147/CMAR.S276519
work_keys_str_mv AT metzdavidc survivalandclinicaloutcomeswithtelotristatethylinpatientswithcarcinoidsyndrome
AT liueric survivalandclinicaloutcomeswithtelotristatethylinpatientswithcarcinoidsyndrome
AT joishvijayn survivalandclinicaloutcomeswithtelotristatethylinpatientswithcarcinoidsyndrome
AT huynhlynn survivalandclinicaloutcomeswithtelotristatethylinpatientswithcarcinoidsyndrome
AT totevtodori survivalandclinicaloutcomeswithtelotristatethylinpatientswithcarcinoidsyndrome
AT duhmeisheng survivalandclinicaloutcomeswithtelotristatethylinpatientswithcarcinoidsyndrome
AT sethkiernan survivalandclinicaloutcomeswithtelotristatethylinpatientswithcarcinoidsyndrome
AT giacalonesusan survivalandclinicaloutcomeswithtelotristatethylinpatientswithcarcinoidsyndrome
AT lapuertapablo survivalandclinicaloutcomeswithtelotristatethylinpatientswithcarcinoidsyndrome
AT morsemichaela survivalandclinicaloutcomeswithtelotristatethylinpatientswithcarcinoidsyndrome